MSL3L2 Inhibitors
Chemical inhibitors of MSL3L2 offer a range of mechanisms by which this protein's activity is hindered, primarily through the alteration of histone modifications that MSL3L2 interacts with or modifies. Trichostatin A and M344 are histone deacetylase (HDAC) inhibitors that increase histone acetylation levels. Elevated acetylation can prevent MSL3L2 from effectively interacting with chromatin, as MSL3L2 may rely on a certain acetylation pattern to bind or modify histones. Sinefungin targets S-adenosylmethionine-dependent methyltransferases, which are important for histone methylation, a process that MSL3L2 is likely involved in. By inhibiting methylation, sinefungin interrupts the methylation-dependent functions of MSL3L2. Chaetocin specifically inhibits SUV39H1, a histone methyltransferase, thus potentially altering the methylation landscape critical for MSL3L2's interaction with chromatin.
Other inhibitors such as BIX-01294 and A-366 selectively target the histone methyltransferase G9a, suggesting that the prevention of methylation at specific histone sites could impede MSL3L2's chromatin remodeling activities. Similarly, UNC1999, GSK343, and EPZ-6438 inhibit EZH2, with UNC1999 also targeting EZH1, which are enzymes responsible for methylating histone sites that MSL3L2 possibly interacts with. The inhibition of these enzymes can alter the chromatin state and thus, the functional capacity of MSL3L2. I-CBP112 and JQ1 disrupt the recognition of acetylated lysine residues by inhibiting the CREBBP/EP300 bromodomains and BET bromodomains, respectively. This inhibition can impede the ability of MSL3L2 to read acetylation marks on histones, which is crucial for its role in chromatin remodeling. Finally, CPI-455, as an inhibitor of KDM5 demethylases, maintains a hypermethylated state on histones, which can interfere with the demethylation activities that MSL3L2 might facilitate, thus hindering its normal function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDACs). Since MSL3L2 is involved in chromatin remodeling through histone modification, HDAC inhibition by Trichostatin A can lead to increased acetylation, which could impede MSL3L2's ability to interact with chromatin and exert its function. | ||||||
M 344 | 251456-60-7 | sc-203124 sc-203124A | 1 mg 5 mg | $109.00 $322.00 | 8 | |
M344 is another HDAC inhibitor that can increase histone acetylation, potentially disrupting the function of MSL3L2 in chromatin remodeling by altering the acetylation status that MSL3L2 might act upon. | ||||||
Sinefungin | 58944-73-3 | sc-203263 sc-203263B sc-203263C sc-203263A | 1 mg 100 mg 1 g 10 mg | $271.00 $5202.00 $40368.00 $704.00 | 4 | |
Sinefungin is an inhibitor of S-adenosylmethionine-dependent methyltransferases, which could inhibit methylation processes that MSL3L2 may be involved in, thus functionally inhibiting MSL3L2's role in histone methylation and chromatin structure. | ||||||
Chaetocin | 28097-03-2 | sc-200893 | 200 µg | $126.00 | 5 | |
Chaetocin is a specific inhibitor of the histone methyltransferase SUV39H1. By inhibiting this enzyme, chaetocin could disrupt the methylation pattern critical for MSL3L2 function in chromatin modification. | ||||||
BIX01294 hydrochloride | 1392399-03-9 | sc-293525 sc-293525A sc-293525B | 1 mg 5 mg 25 mg | $37.00 $112.00 $408.00 | ||
BIX-01294 is an inhibitor of the histone methyltransferase G9a. MSL3L2's chromatin remodeling function can be impaired by altering histone methylation, thus inhibiting the interaction of MSL3L2 with methylated histones. | ||||||
I-CBP112 | 1640282-31-0 | sc-507494 | 25 mg | $400.00 | ||
I-CBP112 is a selective inhibitor of the CREBBP/EP300 bromodomains, which recognizes acetylated lysine residues. By inhibiting these bromodomains, I-CBP112 can disrupt the recognition of acetylated histones by MSL3L2, thereby inhibiting its function. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
UNC1999 is a selective inhibitor of the histone methyltransferases EZH2 and EZH1. It could prevent the methylation of histone sites that MSL3L2 might bind to or modify, thereby functionally inhibiting MSL3L2's role in chromatin remodeling. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 is a small molecule that inhibits the BET family of bromodomains, which could prevent the reading of acetylation marks by MSL3L2, assuming it interacts with such domains, thereby inhibiting its chromatin remodeling activity. | ||||||
GSK343 | 1346704-33-3 | sc-397025 sc-397025A | 5 mg 25 mg | $151.00 $461.00 | 1 | |
GSK343 is a selective inhibitor of EZH2, a histone methyltransferase. By inhibiting EZH2, GSK343 can reduce the methylation at histone sites that could be crucial for the proper function of MSL3L2 in epigenetic regulation. | ||||||
A-366 | 1527503-11-2 | sc-507495 | 10 mg | $195.00 | ||
A-366 is a selective G9a/GLP histone methyltransferase inhibitor, which could prevent methylation of histones at sites where MSL3L2 might exert its activity, thus functionally inhibiting the protein's regulatory role in chromatin organization. | ||||||